A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
La Jolla、California、アメリカ、92093
- Moores UC San Diego Cancer Center
-
La Jolla、California、アメリカ、92037
- Scripps, Clinic General
-
San Diego、California、アメリカ、92123
- Sharp Memorial Hospital
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118
- Boston University Medical Center
-
-
Michigan
-
Lansing、Michigan、アメリカ、48912
- Mid-Michigan Physicians-HOS Division
-
Saint Joseph、Michigan、アメリカ、49085
- Oncology Care Associates
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- CTRC at The University of Texas Health Science Center
-
-
-
-
Maharashtra
-
Pune、Maharashtra、インド、411001
- Jehangir Clinical Development Centre, Jehangir Hospital Premises
-
Pune、Maharashtra、インド、411004
- M.M.F. Joshi Hospital & Ratna Memorial Hospital
-
-
Parel
-
Mumbai、Parel、インド、400012
- Tata Memorial Hospital
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302004
- Birla Cancer Centre, S.M.S. Medical College & Hospital
-
-
-
-
-
Dnipropetrovsk、ウクライナ、49102
- City Multifield Clinical Hospital #4 Department of chemotherapy, Dnipropetrovs'k State Medical Academy, Chair of Oncology and Medical Radiology
-
Lviv、ウクライナ、79031
- State Oncological Regional Treatment and Diagnostic Center Department of chemotherapy
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Hospital University Health Network
-
-
-
-
-
Brussels、ベルギー、1000
- Institut Jules Bordet Unite du Chimiotherapie
-
Gent、ベルギー、9000
- Universitair Ziekenhuis Gent
-
Kortrijk、ベルギー、8500
- AZ Groeninge Campus Maria's Voorzienigheid (MV)
-
Wilrijk、ベルギー、2610
- Oncologisch Centrum GZA - Location St Augustinus
-
-
-
-
-
Krakow、ポーランド、31-826
- Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera, Oddzial Onkologii
-
Lublin、ポーランド、20-090
- Oddzial Chemioterapii Centrum Onkologii Ziemii Lubelskiej
-
-
-
-
-
Beijing、中国、100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Beijing、中国、100032
- Peking Union Medical College Hospital of Chinese Academy of Medical Sciences
-
-
Beijing
-
Beijing、Beijing、中国、100071
- The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army
-
Beijing、Beijing、中国、100853
- Chinese People's Liberation Army General Hospital
-
-
Tianjin
-
TianJin、Tianjin、中国、300060
- Tianjin Cancer Hospital
-
Tianjin、Tianjin、中国、300121
- Tianjin Union Medicine Center Department of Oncology
-
-
-
-
-
Seoul、大韓民国、120-752
- Yonsei University Health System - Severance Hospital
-
Seoul、大韓民国、138-736
- Asan Medical Center, Division of Oncology, Department of Internal Medicine
-
-
-
-
-
Hong Kong、香港
- Department of Medicine, Queen Mary Hospital
-
Hong Kong、香港
- UNIMED Medical Institute
-
Hong Kong、香港
- Department of Surgery Queen Mary Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Inclusion criteria for both parts of clinical trial:
- Good performance status
- Normal ejection fraction
- Adequate cardiac, kidney, and liver function
- Adequate blood counts
- At least one measurable target lesion
- Negative pregnancy test for female subjects
Inclusion Criteria for Part 1 Only:
- Pathologically confirmed solid tumor not curable with available standard therapy
Inclusion Criteria for Part 2 Only:
- Pathologically confirmed breast cancer
- HER2 positive tumor
- Prior treatment with Herceptin
Exclusion Criteria:
Exclusion criteria for both parts of clinical trial:
- Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks of treatment day 1
- Subjects with bone or skin as the only site of disease
- Active central nervous system metastases
- Significant cardiac disease or dysfunction
- Significant gastrointestinal disorder
- Inability or unwillingness to swallow HKI-272 capsules
- Prior exposure to HKI-272 or other HER2 targeted agents, except trastuzumab (Part 2 only). Prior lapatinib is permitted in arm B of part 2.
- Treatment with a taxane within 3 months of treatment day 1
- Grade 2 or greater motor or sensory neuropathy
- Pregnant or breast feeding women
- Known hypersensitivity to paclitaxel or Cremophor EL
- Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2
- Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin
Exclusion Criteria for Part 2 Only:
- More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:HKI-272 dose level 1
Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
|
他の名前:
|
|
実験的:HKI-272 dose level 2
Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
|
他の名前:
|
|
実験的:HKI-272 expanded MTD cohort, arm A
Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
|
他の名前:
|
|
実験的:HKI-272 expanded MTD cohort, arm B
Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
|
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel
時間枠:From first dose date through day 28
|
Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.
|
From first dose date through day 28
|
|
Maximum Tolerated Dose
時間枠:From first dose date through day 28.
|
Maximum Tolerated Dose (MTD) of neratinib, daily, in combination with paclitaxel 80 mg/m², intravenous at days 1, 8, and 15, associated with the dose limiting toxicity data.
|
From first dose date through day 28.
|
|
Objective Response Rate
時間枠:From first dose date to progression or last tumor assessment, up to 140 weeks
|
Subjects with partial response (PR) or complete response (CR) with ERBB2 positive breast cancer treated at the maximum tolerated dose (MTD) of neratinib in combination with paclitaxel, per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0:
CR, disappearance of all target lesions; PR, >=30% decrease in the sum of the longest diameter of target lesions; and no progressive disease (PD) for non-target lesions, and no new lesions.
|
From first dose date to progression or last tumor assessment, up to 140 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum Plasma Concentration of Neratinib
時間枠:Samples taken at 0 hour and at 1, 2, 4, 6, 8, and 24 hours postdose on Day 15 of Cycle 1, and 1 predose sample on Day 1 in Cycle 1.
|
Maximum plasma concentration of neratinib; after each dosing of neratinib on Cycle 1 of Day 15, blood samples taken at regular time points.
|
Samples taken at 0 hour and at 1, 2, 4, 6, 8, and 24 hours postdose on Day 15 of Cycle 1, and 1 predose sample on Day 1 in Cycle 1.
|
|
Area Under the Concentration-time Curve 0-24
時間枠:Samples taken at 0 hour and at 1, 2, 4, 6, 8, and 24 hours postdose on Day 15 of Cycle 1, and 1 predose sample on Day 1 in Cycle 1.
|
Area under the concentration-time curve of neratinib; after each dosing of neratinib on Cycle 1 of Day 15, blood samples taken at regular time points.
|
Samples taken at 0 hour and at 1, 2, 4, 6, 8, and 24 hours postdose on Day 15 of Cycle 1, and 1 predose sample on Day 1 in Cycle 1.
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 3144A1-203 / B1891014
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。